Drug Approval | February 17, 2026
FDA grants priority review to Bristol Myers Squibb's Iberdomide for multiple myeloma
Iberdomide has the potential to be the first approved CELMoD agent
Iberdomide has the potential to be the first approved CELMoD agent
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
Improvements were also seen in complete response rates, duration of response, and time to next treatment
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
FIBROSARC did not meet its primary PFS endpoint in the final analysi
Subscribe To Our Newsletter & Stay Updated
